Author

S. K. Sharan

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 3 Research Focus:drug response / drug discovery· 3 Approach:experimental assay· 3 Organism:mouse· 3 Research Focus:cell type annotation· 2 Research Focus:differential expression· 2 Organism:human· 2 Assay:proteomics· 2

Frequent Co-Authors

A. Fon· 1 shared A. J. Iacovelli· 1 shared A. Kulaga· 1 shared A. M. Michalowski· 1 shared A. R. Chaudhuri· 1 shared A. Raveendran· 1 shared A. Samaiya· 1 shared C. Graff-Cherry· 1 shared

Activity by Year

2019-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 22 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Fon

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Cancer BiologybioRxivPreprintMar 16, 2023

Interferon restores replication fork stability and cell viability in BRCA-defective cells via ISG15

L. Penengo, U. Biswas, R. N. Moro…·S. K. Sharan

This study shows interferon (IFN) improves replication fork stability and cell survival in BRCA-defective cells through ISG15, revealing a new mechanism of drug resistance linked to BRCAness.

DOI 10.1101/2023.03.16.533020

humanmouse

𝕏 PostBluesky

Cancer BiologybioRxivNov 6, 2022

PKM2-mediated epigenetic reprogramming regulates hypoxic expression of PFKFB3 to promote breast cancer progression

M. R. Pandkar, A. Raveendran, K. Biswas…·S. Shukla

This study identifies PKM2's role in hypoxic breast cancer by regulating PFKFB3 expression through epigenetic reprogramming and HIF-1/HIF-2 interactions.

DOI 10.1093/narcan/zcad032

humanmouse

𝕏 PostBluesky

Cancer BiologybioRxivPreprintAug 6, 2019

Multi-model preclinical platform predicts clinical response of melanoma to immunotherapy

E. Perez-Guijarro, H. H. Yang, R. E. Araya…·G. Merlino

The paper develops a preclinical platform using syngeneic mouse models to predict melanoma patient response to immunotherapy and identifies a melanocytic plasticity signature linked to treatment outcomes.

DOI 10.1101/727826

mousebulk RNA-seq

𝕏 PostBluesky